Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Tax Provisions (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Tax Provisions data on record, last reported at $6000.0 in Q4 2025.

  • For Q4 2025, Tax Provisions rose 185.71% year-over-year to $6000.0; the TTM value through Dec 2025 reached -$4.2 million, down 126.45%, while the annual FY2025 figure was -$4.2 million, 126.45% down from the prior year.
  • Tax Provisions reached $6000.0 in Q4 2025 per MRVI's latest filing, up from -$92000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $766.2 million in Q4 2023 and bottomed at -$5.5 million in Q3 2023.
  • Average Tax Provisions over 5 years is $43.6 million, with a median of $291000.0 recorded in 2024.
  • The widest YoY moves for Tax Provisions: up 8970.3% in 2023, down 138.7% in 2023.
  • A 5-year view of Tax Provisions shows it stood at $17.6 million in 2021, then crashed by 51.95% to $8.4 million in 2022, then skyrocketed by 8970.3% to $766.2 million in 2023, then plummeted by 100.0% to -$7000.0 in 2024, then soared by 185.71% to $6000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $6000.0 in Q4 2025, -$92000.0 in Q3 2025, and -$4.3 million in Q2 2025.